What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML?
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consens...
17 Sep 202413min
What were your highlights from ASH 2023?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. Se...
29 Apr 20243min
What are the challenges associated with CAR T-cell therapy in patients with AML?
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therap...
25 Apr 20249min
Risk stratification and guidelines in AML management
The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acut...
8 Jan 202411min
How are new fludarabine conditioning combinations impacting transplant outcomes?
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessalonik...
22 Apr 20226min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatmen...
10 Juli 20216min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be use...
25 Juni 202113min
